540788 ASPIRA

Aspira Pathlab & Diagnostics Share Price

₹66.00 +1.7 (2.64%)

23 Nov, 2024 20:06

SIP TrendupStart SIP in ASPIRA

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 29.54%
  • Over 3 Month + 106.31%
  • Over 6 Month + 113.18%
  • Over 1 Year + 73.68%
SIP Lightning

Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!

Invest Now

Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Aspira Pathlab & Diagnostics Financials

Aspira Pathlab & Diagnostics Technicals

EMA & SMA

Current Price
₹66.00
+ 1.7 (2.64%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹59.36
  • 50 Day
  • ₹50.89
  • 100 Day
  • ₹44.07
  • 200 Day
  • ₹39.39

Resistance and Support

64.87 Pivot Speed
  • R3 75.05
  • R2 71.28
  • R1 68.64
  • S1 62.23
  • S2 58.46
  • S3 55.82

What's your outlook on Aspira Pathlab & Diagnostics?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aspira Pathlab & Diag has an operating revenue of Rs. 14.63 Cr. on a trailing 12-month basis. An annual revenue de-growth of -8% needs improvement, Pre-tax margin of -20% needs improvement, ROE of -26% is poor and needs improvement. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 34% and 79% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 29% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 28 indicates it belongs to a strong industry group of Medical-Services and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-28 Audited Results
2024-02-13 Quarterly Results
2024-02-10 Quarterly Results

Aspira Pathlab & Diagnostics F&O

Aspira Pathlab & Diagnostics Shareholding Pattern

18.55%
61.27%
20.18%

About Aspira Pathlab & Diagnostics

  • NSE Symbol
  • ASPIRA
  • BSE Symbol
  • 540788
  • Managing Director & CEO
  • Dr. Pankaj J Shah
  • ISIN
  • INE500C01017

Similar Stocks to Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics FAQs

Aspira Pathlab & Diagnostics share price is ₹66 As on 23 November, 2024 | 19:52

The Market Cap of Aspira Pathlab & Diagnostics is ₹67.9 Cr As on 23 November, 2024 | 19:52

The P/E ratio of Aspira Pathlab & Diagnostics is -250.7 As on 23 November, 2024 | 19:52

The PB ratio of Aspira Pathlab & Diagnostics is 6.7 As on 23 November, 2024 | 19:52

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23